Gentronix

Gentronix

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500K

Overview

Gentronix is a specialized genotoxicity testing CRO with a strong scientific heritage, originating as a spin-out from the University of Manchester Institute of Science and Technology (UMIST). The company built its reputation on innovative predictive assays like GreenScreen HC and expanded into a full-service CRO offering GLP-compliant regulatory studies. In September 2024, Gentronix was acquired by the Scantox Group, integrating its expertise into a larger toxicology-focused CRO platform to offer broader service capabilities while continuing operations from its base at Alderley Park, Manchester.

Drug DiscoveryToxicology

Technology Platform

Proprietary GreenScreen HC and BlueScreen HC human cell-based reporter assays for predictive genotoxicity screening, complemented by a full suite of OECD/ICH-compliant in vitro and in vivo tests, including the TGRA Big Blue® transgenic rodent model.

Funding History

1
Total raised:$500K
Grant$500K

Opportunities

Growing demand for predictive toxicology to reduce late-stage drug attrition and adhere to the 3Rs (Reduce, Refine, Replace animal testing) principles.
Expansion into testing novel therapeutic modalities and integration with Scantox's broader service portfolio to offer clients a more comprehensive preclinical toxicology package.

Risk Factors

Dependence on client R&D budgets which are subject to economic cycles.
Regulatory changes could impact testing requirements and necessitate costly assay re-validation.
Integration risks following the recent acquisition by the Scantox Group.

Competitive Landscape

Operates in a competitive CRO market with large, full-service players (e.g., Charles River, Labcorp) and other specialized toxicology providers. Differentiates through deep expertise as a pure-play genotoxicity specialist and its proprietary, widely recognized GreenScreen assay platform.